Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: Evaluation of an indicator label

Vox Sanguinis

Volumn 99, Issue 4, 2010, Pages 402-

  Isola, H ^a   Brandner, D ^a   Cazenave, J P ^a   Stahl, E ^a   Corash, Laurence ^b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN;

BLOOD COMPONENT; FRANCE; HEALTH CARE QUALITY; LETTER; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROCESS MONITORING; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; VIRUS INACTIVATION;

HUMANS; PSORALENS; ULTRAVIOLET RAYS; VIRUS DISEASES; VIRUS INACTIVATION; VIRUSES;

EID: 77958513629     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01372.x     Document Type: Letter

References (3)

1. Osselaer JC, Doyen C, Defoin L, et al. : Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use, Transfusion, 2009; 49:1412-1422
2. Cazenave JP, Waller C, Mendel I, et al. : Impact of photochemical treatment of platelet components (INTERCEPT) on platelet and RBC component use by hematology-oncology patients during routine practice, Transfusion, 2008; 48:36A
3. Schlenke P, Hervig T, Isola H, et al. : Photochemical treatment of plsma with amotosalen and UVA light: process validation in three European blood centers, Transfusion, 2008; 48:697-705